WO2017129772A1 - Stable pharmaceutical compositions of temsirolimus - Google Patents

Stable pharmaceutical compositions of temsirolimus Download PDF

Info

Publication number
WO2017129772A1
WO2017129772A1 PCT/EP2017/051815 EP2017051815W WO2017129772A1 WO 2017129772 A1 WO2017129772 A1 WO 2017129772A1 EP 2017051815 W EP2017051815 W EP 2017051815W WO 2017129772 A1 WO2017129772 A1 WO 2017129772A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
acid
temsirolimus
concentration
pharmaceutical composition
composition according
Prior art date
Application number
PCT/EP2017/051815
Other languages
French (fr)
Inventor
Ivona JASPRICA
Vlatka MAKANEC-CEROVECKI
Jelena RANIC
Original Assignee
Xellia Phamaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof

Abstract

The present invention relates to pharmaceutical compositions containing temsirolimus, stabilized with lipoic, caprylic and linoleic acid.

Description

STABLE PHARMACEUTICAL COMPOSITIONS OF TEMSIROLIMUS

Field of the invention

The present invention relates to pharmaceutical compositions containing temsirolimus, which are stabilized with lipoic, caprylic and linoleic acid.

Background of the invention

Temsirolimus (CCI-779), a 42-bis(hydroxymethyl) propionic acid ester derived from rapamycin, selectively inhibits the kinase mammalian target of rapamycin (mTOR) and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors.

Temsirolimus is approved for intravenous administration by the U.S. Food and Drug Administration (FDA) for treatment of advanced renal cell carcinoma (RCC) and by the European Medicines Agency (EMEA) for treatment of advanced renal cell carcinoma and mantle cell lymphoma.

The chemical name of temsirolimus is 42-[3-hydroxy-2-(hydroxymethyl)-2- methylpropanoate]rapamycin and the chemical structure is represented by formula 1 shown below.

Regarding stereochemistry, three isomers A, B and C can exist and they interconvert in solution. Isomer B is the predominant isomer (≥ 97 %) in both solution and solid states, whereas Isomer A is only observed in solution state.

Figure imgf000003_0001

Currently, temsirolimus is marketed as an injectable formulation kit comprising two vials, wherein first concentrate vial contains temsirolimus (25 mg/ml), dehydrated alcohol (39.5% w/v), dl-alpha-tocopherol (0.075% w/v), propylene glycol (50.3% w/v) and anhydrous citric acid (0.0025% w/v); and second diluent vial contains: polysorbate 80 (40.0% w/v), polyethylene glycol 400 (42.8% w/v) and dehydrated alcohol (19.9% w/v).

Temsirolimus concentrate vial must be diluted with the diluent provided in the second vial before addition in sodium chloride 9 mg/ml (0.9%) solution for injection and then administered to the patient in need thereof.

According to the prior art, there are couple of problems to overcome in order to provide a stable temsirolimus composition for parenteral administration:

First, temsirolimus is poorly soluble in aqueous solvents and pH adjustment or salt formations are useless in improving aqueous solubility.

Second, although temsirolimus is soluble in certain organic solvents such as ethanol, propylene glycol, polyethylene glycol and dimethylacetamide, its chemical instability (associated with oxidative degradation or due to the breaking of the lactone bond resulting in the formation of the ring opened compounds) in these solvents and precipitation upon dilution with aqueous infusion solutions is inevitable.

The first aforementioned problem of low solubility in water, as well as precipitation upon dilution with aqueous infusion solution, is resolved by selection of compatible organic co-solvents and addition of a surfactant, while the low chemical stability is enhanced by addition of antioxidant and/or chelating agent in the solution of parenterally acceptable co-solvents as it can be seen from the state of the art:

The marketed composition of temsirolimus includes temsirolimus as the active substance, dl-alpha tocopherol (Vitamin E) as an antioxidant, dehydrated alcohol, propylene glycol and polyethylene glycol 400 as solvents, polysorbate 80 as a surfactant, and anhydrous citric acid as a stabilizer.

WO200401 1000 provides parenteral formulations of rapamycin 42- ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) wherein acceptable antioxidants include citric acid, dl-alpha-tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, propyl gallate, and mixtures thereof.

U.S. Application US201 2252835 describes a stable composition of temsirolimus for parenteral administration wherein the composition includes butylated hydroxyanisole (BHA) or butylated hydroxytoluene (BHT) as antioxidants and alcoholic solvent and the pH of the composition is below 5.0.

In WO20141 18696, liquid and lyophilized pharmaceutical compositions comprising temsirolimus in combination with an organic acid, inorganic acid and amino acid are provided. Examples of organic acid include ascorbic acid, citric acid, tartaric acid, lactic acid, oxalic acid, formic acid, benzene sulphonic acid, benzoic acid, maleic acid, malonic acid, glutamic acid, succinic acid, aspartic acid, diatrizoic acid, acetic acid and mixtures thereof. Examples of inorganic acid include hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid and mixtures thereof. Examples of amino acid include cysteine, glycine, alanine, lysine, arginine, glutathione, methionine, leucine, aspartic acid and mixtures thereof. Also, addition of antioxidants selected from citric acid, dl-alpha-tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, propyl gallate and mixtures thereof is disclosed. In WO201 1 1 51 704 , pharmaceutical antioxidant-free compositions of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid are provided, in particular comprising parenterally acceptable solvent, lactic acid and a surfactant. In WO200501 001 0 , purified CCI-779 isomer C is provided, as are pharmaceutical compositions containing the same, wherein antioxidant is selected from citric acid, dl-alpha-tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, propyl gallate, and mixtures thereof. WO200608931 2 provides CCI-779 oral dosage form in which acceptable antioxidants include citric acid, dl-alpha-tocopherol, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), monothioglycerol, ascorbic acid, propyl gallate, and mixtures thereof. WO2007075621 provides a method of preparing a rapamycin composition having increased potency wherein the method involves selecting a rapamycin compound having less than 1.5% oxidative and hydrolytic rapamycin impurities and formulating the selected rapamycin with an antioxidant and optional excipients. Antioxidants that can be used include citric acid, alpha tocopherol, BHA, BHT (2,6-di-tert-butyl-4-methylphenol), monothioglycerol, vitamin C, and propyl gallate. In Chinese publication CN1 03099806, temsirolimus for injection is described, wherein suitable antioxidants are alpha-tocopherol, ascorbic acid, sodium bisulfite and citric acid. In CN 1 03989676 , a liquid composition of temsirolimus, ethyl alcohol, organic acid and propylene glycol is disclosed.

Various prior art documents aim at solving the problem with chemical instability of solid temsirolimus compositions in form of antioxidant addition :

PCT publication WO0033878 relates to the stabilization of a pharmaceutically active ingredient sensitive to oxidation, particularly rapamycins. Preferred antioxidants according to the description are 2,6-di- tert-butyl-4-methylphenol (BHT), vitamin E or C, wherein BHT being particularly preferred.

WO200501 1 688 discloses lyophilized CCI-779 formulations and solutions useful for preparing freeze-dried CCI-779 formulations wherein examples of suitable antioxidants include BHT, BHA, alpha-tocopherol, ascorbic acid, erythorbic acid, dithiothreitol, dithioerythreitol, glutathione, ascorbyl palmitate, monothioglycerol, propyl gallate, sodium bisulfite, sodium metabisulfite.

WO2004026280 provides solid oral formulations of rapamycin 42- ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779). Acceptable antioxidants include, but are not limited to, citric acid, dl-alpha- tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, and propyl gallate.

The invention described in WO2005070393 provides pharmaceutical compositions containing a stable and bioavailable form of micronized CCI- 779, and optionally, an antioxidant or a chelating agent, or mixtures thereof, in an immediate release dosage form for oral administration . Acceptable antioxidants include citric acid, dl-alpha-tocopherol, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), monothioglycerol, ascorbic acid, propyl gallate, and mixtures thereof. According to the prior art described above, the challenge of the moment is how to provide temsirolimus compositions where oxidative/hydrolytic degradation and quality decline is prevented. As can be seen from the marketed formulation, as well as from prior art, it is crucial to have an antioxidant present in the formulation to prevent degradation of the drug.

However, inventors of the present invention have surprisingly found that various lipophilic acids - with or without antioxidant properties stabilize rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid in organic solvents.

Sum mary of t he invention

Oxidation is one of the major processes that have destructive effect on stability of a drug. In order to provide a stable pharmaceutical formulation, active pharmaceutical ingredients susceptible to chemical degradation by oxidation are often formulated with antioxidants whose main purpose is to retard or inhibit the oxidative breakdown of active ingredients upon exposure to atmospheric oxygen and to improve the shelf life of such products.

Some of the most common antioxidants used in pharmaceutical industry are butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium metabisulfite, propyl gallate, cysteine, tocopherols and ascorbic acid. In recent studies, some of these excipients are reported to be associated with adverse reactions, therefore, the need to find less or nontoxic excipients as alternative ways of stabilization of pharmaceutical preparations is emerging.

According to the present invention, lipophilic acids selected from the group consisting of caprylic (octanoic), lipoic and linoleic acid are used as stabilizing agents, and they show surprisingly good stabilizing effect on temsirolimus.

Caprylic acid, also known by the systematic name octanoic acid, is a saturated fatty acid containing eight carbon atoms, making it one of the medium-chain fatty acids. Caprylic acid, a naturally occurring constituent of many foods, is absorbed and metabolized by man. Some studies have shown that caprylic acid has antibacterial, antiviral and antifungal properties. Caprylic acid is also taken as a dietary supplement.

Figure imgf000008_0001

Lipoic acid or l,2-dithiolane-3-pentanoic acid, also known as thioctic acid, is a naturally occurring dithiol compound synthesized enzymatically in the mitochondrion from octanoic acid. Lipoic acid has been described as a potent biological antioxidant, a detoxification agent, and a diabetes medicine; it has been used to improve age-associated cardiovascular, cognitive, and neuromuscular deficits, and has been implicated as a modulator of various inflammator signaling pathways.

Figure imgf000008_0002
Linoleic acid is a polyunsaturated omega-6 fatty acid.

Figure imgf000009_0001
The newly developed pharmaceutical compositions, according to the present invention, show chemical stability comparable to the marketed product and even better chemical stability than those formulations known from the prior art containing other commonly used antioxidants, when they are stored at 40°C, 25°C or 2-8°C for a period ranging from 1 week to 6 (12) months.

This invention, in one embodiment, provides a parenteral formulation containing temsirolimus, an organic solvent selected from ethanol, propylene glycol, polyethylene glycol or combinations thereof; a surfactant selected from polysorbate 20 or polysorbate 80; citric acid as a chelating/stabilizing agent and lipophilic acid selected from caprylic, lipoic, and linoleic acid.

In a second embodiment, invention is provided in two vials kit, comprising a first vial comprising temsirolimus and a second vial comprising a diluent, wherein the first vial contains temsirolimus in concentration of 20 to 30 mg/ml_, preferably 25 mg/ml_, an organic solvent selected from ethanol, propylene glycol, polyethylene glycol or combinations thereof from about 10% to about 90% w/v of the formulation; citric acid in a concentration of 0.001 to 0.005% w/v and lipophilic acid selected from caprylic, lipoic, and linoleic acid in a concentration ranging from 0.001% to 1% w/v, or 0.01% to 0.5% w/v, although lower or higher concentrations may be desired. Particularly desirable concentration of lipophilic acid is from 0.01 to 0.1% w/v, with a most preferred concentration of 0.075% w/v. According to the second embodiment, the second diluent vial contains an organic solvent selected from ethanol, propylene glycol, polyethylene glycol or combinations thereof, and a surfactant selected from polysorbate 20 or polysorbate 80 wherein the surfactant will comprise at least 5% w/v, or at least 10% w/v, of the diluent solution.

In a third embodiment, compositions according to the present invention are provided in two vials kit, comprising a first vial comprising temsirolimus and a second vial comprising a diluent, wherein the first vial contains temsirolimus in a concentration of 25 mg/ml_, dehydrated ethanol in a concentration of 39.5% w/V, propylene glycol in a concentration of 50.3% w/V, citric acid in a concentration 0.0025% w/V and lipophilic acid selected from caprylic, lipoic, and linoleic acid in a concentration 0.075% w/V.

According to the third embodiment, the second diluent vial contains polysorbate 80 in a concentration of 40.0% w/v, polyethylene glycol 400 in a concentration of 42.8% w/v and dehydrated ethanol in a concentration of 19.9% w/v.

According to the present invention, when compositions are provided as two vials kit, prior to administration to a patient, content of the two vials are mixed together and added into the infusion fluid.

Temsirolimus compositions described herein are useful for the treatment of renal cell carcinoma and mantle cell lymphoma .

Other objects, features and advantages of the present invention will become apparent from the following detailed description and examples. It should be understood, however, that the detailed description and the examples, while indicating specific embodiments of the invention, are given by way of illustration only. Detailed description of the invention

The term "pharmaceutical composition" as used herein, means a composition that is made under conditions such that it is suitable for administration to a patient and contains pharmaceutically acceptable excipients, e.g. without limitation to stabilizers, bulking agents, surfactants, buffers, carriers, diluents, vehicles, solubilizers and binders.

As used herein, the terms "pharmaceutical composition", "pharmaceutical formulation", "composition" and "formulation" are used interchangeably.

Term "stable" here refers to a pharmaceutical formulation containing temsirolimus having sufficient stability to have utility as a pharmaceutical product and meets defined shelf life specifications for this product as a marketed product.

Preferably, a stable pharmaceutical composition has sufficient stability to allow storage at a convenient temperature, wherein the storage temperature is preferably from 2°C to 30°C, more preferably from 2°C to 25°C, and even more preferably from 2°C to 8°C, for a reasonable period of time, e.g. the shelf-life of the product which can be as short as one month but is typically 12 months or longer.

Temsirolimus is known to degrade at a really fast rate and alternative methods for preparation of temsirolimus compositions that have good chemical stability and therefore less degradation impurities formation over time are needed.

In order to determine the degradation profile of temsirolimus in the presence of antioxidants, known antioxidants suggested from the prior art and general literature such as alpha-tocopheryl hydrogen succinate, monothioglycerol, sodium-lactate, N-acetylcysteine, ascorbic acid, gentisic acid and ascorbyl-palmitate were tested and data obtained are presented below.

As can be seen from the following results, most of the suggested antioxidants did not work toward stabilization of temsirolimus. To the contrary, the suggested antioxidants promoted the decomposition of temsirolimus and formation of impurities.

Unexpectedly, acids selected from caprylic, lipoic and linoleic acid, showed good stabilization effect on temsirolimus and slower rate of impurities formation.

The following compositions were prepared and tested :

1. Composition similar to the marketed product with concentration of alpha- tocopherol of 0.075% w/V

Figure imgf000012_0001

2. Composition wherein alpha-tocopherol was used in higher concentration of 0.45% w/V

Figure imgf000012_0002

3. Compositions wherein alpha-tocopherol was replaced with antioxidants suggested in the prior art and selected from group consisting of alpha- tocopheryl hydrogen succinate, monothioglycerol, sodium-lactate, N- acetylcysteine, ascorbic acid, gentisic acid, and ascorbyl-palmitate in a concentration of 0.075% w/V

Figure imgf000012_0003
4. Compositions of temsirolimus, which contain lipophilic acids according to this invention in concentration of 0.075% w/V

Figure imgf000013_0001

5. Composition of temsirolimus without addition of antioxidants

Figure imgf000013_0002

The following examples were provided in two vial compositions of temsirolimus wherein the compositions of the vials were prepared as described below:

Preparation of the content of the first vial - concentrate:

The temperature of the solution in the formulation vessel is maintained at 2-8°C and the solution is protected from light throughout the compounding process. Approximately 50% of the required quantity of propylene glycol is added into the formulation vessel. Then, required quantity of citric acid is added and solution is stirred until complete dissolution.

Separately, stock solution of lipophilic acid or antioxidant is prepared in 20-30% of total quantity of dehydrated ethanol and added into formulation vessel under constant stirring. Alternatively, lipophilic acid or antioxidant is added directly into formulation vessel and stirred.

The remainder of total required quantity of dehydrated ethanol is then added into formulation vessel. At this stage, temsirolimus is slowly added into formulation vessel under constant stirring. After complete dissolution is achieved, volume is made up to 100% with propylene glycol and then solution is purged with nitrogen to achieve dissolved oxygen content of not more than 2 ppm. This solution is filtered through a suitable 0.22 μηι sterilizing grade filter, filled in Type I clear glass vials and overlayed with nitrogen, prior stoppering with suitable Type I rubber stoppers.

Preparation of the second diluent vial :

Solution is prepared in the formulation vessel at room temperature

(18-25°C) . Firstly, required amount of polyethylene glycol is added to the formulation vessel . Under constant stirring, required quantity of polysorbate 80 is added to the formulation vessel, with subsequent addition of approximately 40% of the required quantity of dehydrated ethanol . Solution is mixed until complete mixing of components is achieved. Volume is made up to 100% with dehydrated ethanol and then solution is purged with nitrogen to achieve dissolved oxygen content of not more than 2 ppm. This solution is filtered through a suitable 0.22 μηι sterilizing grade filter, filled in Type I clear glass vial and overlayed with nitrogen, prior stoppering with suitable Type I rubber stoppers.

Immediately after preparation of every individual composition, analysis for initial assay and related substances content followed, and afterwards compositions were loaded in stability chambers for stress testing at 40°C/75% RH; accelerated stability testing at 25°C/60% RH and long term stability testing at 2-8°C.

Temsirolimus assay and related substances were determined using routine HPLC methods known to those skilled in the art, for example as described in U.S Application Publication No. 2007/0142422.

Analysis of the formulations of the present invention can be performed using other techniques known in the art, including, for example, gas chromatography, and NMR.

In the tables presented below, assay of active substance - temsirolimus, is expressed as a content of isomer B and isomer C. Isomer A is monitored as a separate value and it is not included in total impurities content. It has been observed that compositions of temsirolimus when formulated with lipophilic acid selected from caprylic, lipoic, and linoleic acid show comparable or even better chemical stability in comparison to chemical stability obtained by addition of known antioxidants selected from alpha- tocopherol, alpha-tocopheryl hydrogen succinate, monothioglycerol, sodium- lactate, N-acetylcysteine, ascorbic acid, gentisic acid and ascorbyl-palmitate.

Figure imgf000016_0001

Figure imgf000017_0001

Figure imgf000018_0001

Claims

CLAIMS 1. Pharmaceutical composition comprising temsirolimus and a lipophilic acid selected from the group consisting of caprylic, lipoic and linoleic acid. 2. Pharmaceutical composition according to claim 1, wherein concentration of lipophilic acid is from 0.001% to 1% w/v. 3. Pharmaceutical composition according to claim 1, wherein concentration of lipophilic acid is from 0.01% to 0.5% w/v. 4. Pharmaceutical composition according to claim 1, wherein concentration of lipophilic acid is from 0.01 to 0.1% w/v. 5. Pharmaceutical composition according to any one of claims 1 to 4, comprising an organic solvent selected from ethanol, propylene glycol, polyethylene glycol or combinations thereof; and citric acid as a chelating/stabilizing agent. 6. Pharmaceutical composition according to claim 5, further comprising a surfactant selected from polysorbate 20 or polysorbate 80. 7. Pharmaceutical composition according to any one of claims 1 to 5, wherein concentration of temsirolimus is from 20 to 30 mg/mL. 8. Pharmaceutical composition according to any one of claims 1 to 5, wherein concentration of temsirolimus is 25 mg/mL. 9. Pharmaceutical composition according to claim 1, comprising temsirolimus in a concentration of 25 mg/mL, dehydrated ethanol in a concentration of 39.5% w/V, propylene glycol in a concentration of 50.3% w/V, citric acid in a concentration 0.0025% w/V and a lipophilic acid selected from caprylic, lipoic, or linoleic acid in a concentration 0.075% w/V. 10. Pharmaceutical composition according to any of the preceding claims 1-9 for use in treatment of renal cell carcinoma and mantle cell lymphoma.
Two vials kit, comprising (i) a first vial comprising temsirolimus and a lipophilic 1 1.
acid selected from the group consisting of caprylic, lipoic and linoleic acid, and (ii) a second vial comprising a diluent.
PCT/EP2017/051815 2016-01-29 2017-01-27 Stable pharmaceutical compositions of temsirolimus WO2017129772A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201662288713 true 2016-01-29 2016-01-29
US62/288,713 2016-01-29

Publications (1)

Publication Number Publication Date
WO2017129772A1 true true WO2017129772A1 (en) 2017-08-03

Family

ID=57906638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/051815 WO2017129772A1 (en) 2016-01-29 2017-01-27 Stable pharmaceutical compositions of temsirolimus

Country Status (1)

Country Link
WO (1) WO2017129772A1 (en)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033878A2 (en) 1998-12-07 2000-06-15 Novartis Ag Stabilization of macrolides
WO2004011000A1 (en) 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
WO2004026280A2 (en) 2002-09-17 2004-04-01 Wyeth Granulate formulation of the rapamycin ester cci-779
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
WO2005011688A1 (en) 2003-07-25 2005-02-10 Wyeth Cci-779 lyophilized formulations
WO2005070393A2 (en) 2004-01-08 2005-08-04 Wyeth Directly compressible pharmaceutical composition of the rapamycin ester cci-779
WO2006089312A2 (en) 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
US20070142422A1 (en) 2005-12-20 2007-06-21 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
WO2010056754A2 (en) * 2008-11-11 2010-05-20 The Board Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US20120071349A1 (en) * 2009-04-10 2012-03-22 Haiyan Qi Novel anti-aging agents and methods to identify them
US20120087959A1 (en) * 2009-06-19 2012-04-12 Sun Pharma Advanced Research Company Limited Nanodispersion of a drug and process for its preparation
US20120252835A1 (en) 2011-04-01 2012-10-04 Astron Research Limited Stable temsirolimus composition and process of preparing same
CN103099806A (en) 2011-11-11 2013-05-15 山东新时代药业有限公司 Temsirolimus for injection and preparation method thereof
WO2014118696A2 (en) 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
CN103989676A (en) 2014-06-10 2014-08-20 福建省微生物研究所 Injectable temsirolimus composition

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033878A2 (en) 1998-12-07 2000-06-15 Novartis Ag Stabilization of macrolides
WO2004011000A1 (en) 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
WO2004026280A2 (en) 2002-09-17 2004-04-01 Wyeth Granulate formulation of the rapamycin ester cci-779
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
WO2005011688A1 (en) 2003-07-25 2005-02-10 Wyeth Cci-779 lyophilized formulations
WO2005070393A2 (en) 2004-01-08 2005-08-04 Wyeth Directly compressible pharmaceutical composition of the rapamycin ester cci-779
WO2006089312A2 (en) 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
US20070142422A1 (en) 2005-12-20 2007-06-21 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
WO2007075621A1 (en) 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
WO2010056754A2 (en) * 2008-11-11 2010-05-20 The Board Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US20120071349A1 (en) * 2009-04-10 2012-03-22 Haiyan Qi Novel anti-aging agents and methods to identify them
US20120087959A1 (en) * 2009-06-19 2012-04-12 Sun Pharma Advanced Research Company Limited Nanodispersion of a drug and process for its preparation
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US20120252835A1 (en) 2011-04-01 2012-10-04 Astron Research Limited Stable temsirolimus composition and process of preparing same
CN103099806A (en) 2011-11-11 2013-05-15 山东新时代药业有限公司 Temsirolimus for injection and preparation method thereof
WO2014118696A2 (en) 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
CN103989676A (en) 2014-06-10 2014-08-20 福建省微生物研究所 Injectable temsirolimus composition

Similar Documents

Publication Publication Date Title
US6040330A (en) Pharmaceutical formulations of taxanes
US20110184036A1 (en) Formulations of bendamustine
WO1997023208A1 (en) Taxane composition and method
WO2003053350A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
US20050020615A1 (en) CCI-779 lyophilized formulations
US20080226710A1 (en) Ubiquinol and alpha lipoic acid compositions
US7772274B1 (en) Docetaxel formulations with lipoic acid
US20130210879A1 (en) Formulations of bendamustine
WO2006133510A1 (en) Liquid pharmaceutical formulations of docetaxel
WO1998005314A1 (en) Novel stable liquid paracetamol compositions, and method for preparing same
US20090325978A1 (en) Stable lyophilized preparation
US20080319048A1 (en) Solubilized formulation of docetaxel without tween 80
US20120065255A1 (en) Cabazitaxel formulations and methods of preparing thereof
US20040171560A1 (en) Stabilized pharmaceutical composition
US6071974A (en) Limpid parenteral solution of 2,6-diisoprophylphenol as an anaesthetic drug and 2.5-di-O-methyl-1.4;3.6-dianhydro-D-glucitol as a solvent for making clear I. V. formulation
US6710195B2 (en) Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
WO2005020980A1 (en) Acid containing oxaliplatin formulations
US6143795A (en) Stable mitoxantrone solutions
KR101260636B1 (en) A stabilized pemetrexed preparation
US20080103121A1 (en) Cephalosporin derivative formulation
US20080139644A1 (en) Composition comprising (-)-delta9-trans-tetrahydrocannabinol
WO2004071502A1 (en) Injectable liquid formulation of paracetamol
CN1553815A (en) Pharmaceutical formulation for the intramuscular administration of fulvestrant
WO2007085067A1 (en) Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same.
US20120172808A1 (en) Stable Bortezomib Formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17701713

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE